Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Biotechnology

Healthcare
$4.26 +2.67%

+$0.19 today

Market cap
$71.70M
Beta
1.52
P/E (TTM)
0.0
EPS (TTM)
$407.81
52W Low $6.42High $31.50

Volume 0.06M

Average 0.44M

ENLV Other Stockholders Equity

Equity items not reported separately, such as additional paid-in capital or treasury stock.

Enlivex Therapeutics Ltd.NASDAQ: ENLV

Other Stockholders Equity · Q4 FY2025 · quarter ended Dec 2025

Other stockholders equity remains negative

Q4 FY2025 other stockholders equity was $0, compared with $0 a year earlier.

Context

  • Other stockholders equity amounted to 0.0% of total assets at the end of Q4 FY2025, unchanged from a year earlier.
  • Other stockholders equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoDec 2024
$0— since
Other Stockholders Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Stockholders Equity history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Other Stockholders Equity vs competitors

How ENLV compares with its peers on the latest reported figures

  • ENLV's Dec 2025 other stockholders equity of $0 is the highest of the 2 companies compared; the peer median is $0.
  • Other stockholders equity amounts to 0.0% of total assets for ENLV, versus a peer median of 0.0%.
ENLV Competitors Peer median
Other Stockholders Equity for ENLV and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ENLVEnlivex Therapeutics Ltd.Dec 2025$0 ——0.0%
NRXSNeurAxis, Inc.Mar 2026$0 ——0.0%
Peer median (excluding ENLV) $0——0.0%

Competitors are the stored peer set for ENLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents11.2M49.95M813K3.3M2.01M
Short-term Investments72.93M299K26.51M20.2M3.86M
Net Receivables1.09M647K229K1.3M235K
Inventory01.18M000
Other Current Assets113K(1.18M)5.11M198K1.73B
Total Current Assets86.44M52.33M33.76M25.99M1.74B
Property, Plant & Equipment (Net)8.22M14.9M2.58M1.15M938K
Goodwill00000
Intangible Assets0000582.51M
Long-term Investments3K0308K531K374K
Tax Assets00000
Other Non-current Assets482K412K179K10K0
Total Non-current Assets8.7M15.31M3.07M1.69M583.82M
Total Assets95.15M67.64M36.83M27.69M2.33B
Account Payables878K1.95M827K811K3.81M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities001.57M142K1.89M
Total Current Liabilities4.72M6.61M6.06M3.8M9.02M
Long-term Debt00000
Deferred Tax Liabilities0000382.65M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities5.39M4.19M686K299K383.03M
Total Liabilities10.11M10.8M6.75M4.1M392.05M
Common Stock2.11M2.12M2.14M2.69M28.73M
Retained Earnings(51.97M)(83.03M)(112.09M)(127.11M)1.11B
Accumulated OCI1.1M1.1M1.1M1.1M1.1M
Other Stockholders Equity00000
Minority Interest00000
Total Equity85.04M56.84M30.08M23.59M1.93B
Total Debt6.01M4.85M1.03M534K641K
Net Debt(5.2M)(45.1M)219K(2.77M)(1.37M)

Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Intrinsic Alpha fair value

Locked

Current Price

$4.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.